Relypsa Announces Appointment of John Orwin as Chief Executive Officer

  Relypsa Announces Appointment of John Orwin as Chief Executive Officer

   Industry Veteran Brings Extensive Senior Biopharma Background from Firms
                  including Genentech and Johnson & Johnson

Business Wire

SANTA CLARA, Calif. -- May 15, 2013

Relypsa, Inc., a biopharmaceutical company advancing lead product candidate,
patiromer (RLY5016) for the treatment of hyperkalemia, in a pivotal Phase 3
clinical study, announced today the appointment of John Orwin as Chief
Executive Officer of Relypsa. Mr. Orwin brings over 20 years of diverse
experience in the biotechnology and pharmaceutical industries, having held
senior positions at leading pharmaceutical and biotechnology companies,
including Johnson & Johnson, Affymax, Rhone-Poulenc Rorer and Genentech.
Previously, Relypsa has been headed by President and Founder Gerrit Klaerner,
Ph.D., who will remain on as a consultant. Mr. Orwin’s appointment will be
effective no later than June 17th.

“John’s background as a senior leader in the life sciences industry will be
invaluable as Relypsa approaches completion of the Company’s patiromer
clinical program, being conducted under an agreed-upon SPA with the FDA,” said
Scott M. Rocklage, Ph.D., Relypsa’s Chairman. “The Company currently is
preparing to commercialize patiromer in the U.S., with an expected NDA
submission in 1Q 2014, and I anticipate John’s background in marketing, sales
and general management will prove critical to the success of the potential
launch of patiromer.” Dr. Rocklage continued, “We are grateful for Gerrit’s
stewardship of the Company and his enduring commitment to Relypsa’s success.
No doubt his insights will continue to have a profound impact on the
advancement of patiromer.”

Mr. Orwin stated, “I am excited to join the Relypsa team, which is advancing a
breakthrough product for areas of immense patient need – chronic kidney
disease and heart failure. The team’s accomplishments at Relypsa are extensive
– innovative product design, creation of a strong, protective patent estate,
proof-of-concept validation with positive Phase 2 data, and rapid execution of
the Phase 3 program, among others. All of these were compelling reasons for me
to join the team at Relypsa, and I look forward to continued progress of the
clinical program and submission for commercial entry in the U.S. market.”

About John Orwin

Mr. Orwin served as chief executive officer and a member of Affymax’s board of
directors starting in February 2011. From April 2010 to January 2011, he
served as president and chief operating officer of Affymax. From 2005 to 2010,
Mr. Orwin served as vice president and then senior vice president, BioOncology
Business Unit, at Genentech, where he was responsible for all marketing,
sales, business unit operations and pipeline brand management for Genentech's
oncology portfolio in the United States. From 2001 to 2005, Mr. Orwin served
in various executive-level positions at Johnson & Johnson, overseeing oncology
therapeutic commercial and portfolio expansion efforts in the US. He has also
held senior marketing and sales positions at Alza Pharmaceuticals, Sangstat
Medical Corporation, Rhone-Poulenc Rorer Pharmaceuticals and Schering-Plough
Corporation. Mr. Orwin holds an M.B.A. from New York University and a B.A.
from Rutgers University.

About Patiromer and Hyperkalemia

Hyperkalemia is a condition frequently prevalent in patients that suffer from
renal impairment, hypertension, diabetes and/or heart failure. It is
characterized by elevated serum potassium levels, which can lead to cardiac
arrhythmia and sudden death. Patients with chronic kidney disease are at
particular risk for developing hyperkalemia, especially those treated with
renin-angiotensin-aldosterone-system (RAAS) inhibitors. Although RAAS
inhibition has been shown to protect kidney and cardiac function, as well as
prolong life, many patients who could benefit from RAAS inhibitors are
untreated or undertreated due to the undesirable side effect of increasing
serum potassium.

Patiromer (RLY5016) is a high capacity non-absorbed oral potassium binder
being developed for the management of elevated serum potassium levels. Relypsa
has completed several clinical trials of patiromer that have demonstrated the
preliminary efficacy, safety and tolerability of patiromer for the treatment
of hyperkalemia.

About Relypsa, Inc.

Relypsa, Inc. is a late clinical-stage biopharmaceutical company leading the
discovery and development of novel non-absorbed polymeric drugs for important
applications in cardiovascular and renal diseases. Relypsa's lead product
candidate is patiromer, a non-absorbed potassium binder for the treatment of
hyperkalemia. Relypsa is pursuing the discovery of additional product
candidates through use of its proprietary polymer platform. More information
is available at


Relypsa, Inc.
Kristine Ball, SVP, Chief Financial Officer
Press spacebar to pause and continue. Press esc to stop.